Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Although life prevalence of substance use disorders among patients with schizophrenia is close to 50%, few studies have been carried out to date to identify an integrated pharmacological treatment for this comorbidity. So far, the most promising results, that we report here, have been obtained with clozapine. To a lesser extent, quetiapine and olanzapine, both clozapine analogues, have also shown promising results. Further to these observations, the present paper critically reviews the advantages associated with clozapine, quetiapine and olanzapine, and their relevance to the treatment of addiction among schizophrenic patients. Six characteristics seem to distinguish clozapine, quetiapine and olanzapine from the first-generation antipsychotics: (1) acting preferentially on the reward system, these second-generation antipsychotics (mainly clozapine and quetiapine) induce almost no extrapyramidal symptoms; (2) quickly dissociating from D(2), theses drugs (mainly clozapine and quetiapine) seem not to induce dysphoria, unlike conventional antipsychotics like haloperidol;(3) these drugs (mainly clozapine) seem more effective in the treatment of negative symptoms than conventional antipsychotics; (4) because of a diversified activity on several serotoninergic and noradrenergic receptors, these drugs positively alter mood, which does not seem to be the case with conventional antipsychotics, except for flupenthixol; (5) these drugs have a positive impact on cognition, which is not the case with the first-generation antipsychotics; (6) unlike conventional antipsychotics, these drugs seem to have a moderate affinity for 5-HT(3), the receptor on which ondansetron, an anti-craving medication, acts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Self-Medication Hypothesis of Substance Use Disorders: A Reconsideration and Recent Applications
Khantzian, E. J. (1997) · Harvard Review of Psychiatry · doi:10.3109/10673229709030550 · Cited by 3,242 · cited 4×
“(Khantzian, 1997).”
BackgroundMethodInfluentialAntipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
Breier, A., Su, T.-P., Saunders, R., Carson, R. E., Kolachana, B. S., de Bartolomeis, A., Weinberger, D. R., Weisenfeld, N., Malhotra, A. K., Eckelman, W. C., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2569 · Cited by 1,154 · cited 1×
“…(Lauer et al., 2001); (ix) as measured by PET or single-photon emission computed tomography (SPECT), the release of dopamine in the striatum, after the administration of amphetamines, is greater in schizophrenics than in normal subjects (Breier et al., 1997; Laruelle and Abi-Dargham, 1999).”
BackgroundSchizophrenia: A neural diathesis-stress model.
Walker, E. F., & Diforio, D. (1997) · Psychological Review · doi:10.1037//0033-295x.104.4.667 · Cited by 930
Atypical antipsychotics: Mechanism of action
Seeman, P. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700106 · Cited by 899
Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria
Drevets, W. C., Gautier, C., Price, J. C., Kupfer, D. J., Kinahan, P. E., Grace, A. A., Price, J. L., & Mathis, C. A. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01038-6 · Cited by 706 · cited 2×
“, 2001); (v) in humans, amphetamine-induced euphoria in normal subjects is accompanied by an activation of the ventral striatum (Drevets et al., 2001); (vi) antipsychotics share”
BackgroundDrug abuse in schizophrenic patients: clinical correlates and reasons for use
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.2.224 · Cited by 547 · cited 2×
“When questioned, addicted schizophrenics report that they abuse psychoactive substances in order to relieve negative affects (Dixon et al. 1991).”
BackgroundSubstance use disorders in schizophrenia: review, integration, and a proposed model
Blanchard, J. (2000) · Clinical Psychology Review · doi:10.1016/s0272-7358(99)00033-1 · Cited by 240 · cited 1×
“(1997) Results are preliminary Negative affect/stress relief Blanchard et al. (2000) Schizophrenics addicted to alcohol are generally more depressed Reward deficiency/biological vulnerability Green et al.”
BackgroundThe anhedonia hypothesis: mark III.
Wise, R. A. (1985) · Behavioral and Brain Sciences · doi:10.1017/s0140525x00020306 · Cited by 169 · cited 1×
“Following the classic work by Wise (1985) with rodents, it has been suspected that the haloperidol-generation antipsychotics induce anhedonia or a loss of motivation because of their strong D2 antagonism.”
BackgroundWachtel, S. R., Ortengren, A., & Wit, H. D. (2002) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(02)00104-7 · Cited by 138
Cited by
Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Möller, H.-J., WFSBP Task Force on Treatment Guide, Falkai, P., Wobrock, T., Lieberman, J., et al. (2006) · The World Journal of Biological Psychiatry · doi:10.1080/15622970500483177 · Cited by 331
The 5-HT3receptor as a therapeutic target
Thompson, A. J., & Lummis, S. C. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.4.527 · Cited by 257
Baker, A., Richmond, R., Haile, M., Lewin, T. J., Carr, V. J., Taylor, R. L., Jansons, S., & Wilhelm, K. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1934 · Cited by 255
Abler, B., Erk, S., & Walter, H. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0690-y · Cited by 118
“2002) and was suggested a valuable treatment of addiction in schizophrenic patients (Potvin et al. 2003).”
BackgroundInfluentialValeriani, G., Corazza, O., Bersani, F. S., Melcore, C., Metastasio, A., Bersani, G., & Schifano, F. (2015) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2431 · Cited by 41
Metadata
- Authors
- Potvin, S., Stip, E., & Roy, J.-Y.
- Venue
- International Clinical Psychopharmacology
- Published
- 2003-05
- Volume
- 18
- Issue
- 3
- Pages
- 121-132
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2029931114
- Cited by
- 58
- References
- 10
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses. https://app.cochat.ai/papers/10.1097/01.yic.0000063501.97247.38
- The paper
- Potvin, S., Stip, E., & Roy, J.-Y. (2003). Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses. International Clinical Psychopharmacology. https://doi.org/10.1097/01.yic.0000063501.97247.38
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.